SEARCH

SEARCH BY CITATION

REFERENCES

  • Anderson J, Burns HD, Enriquez-Harris P, Wilkie AO, Heath JK. 1998. Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand. Hum Mol Genet 7: 14751483.
  • Boulet SL, Rasmussen SA, Honein MA. 2008. A population-based study of craniosynostosis in metropolitan Atlanta, 1989–2003. Am J Med Genet Part A A146A: 984991.
  • Bourgeois P, Bolcato-Bellemin AL, Danse JM, Bloch-Zupan A, Yoshiba K, Stoetzel C, Perrin-Schmitt F. 1998. The variable expressivity and incomplete penetrance of the twist-null heterozygous mouse phenotype resemble those of human Saethre-Chotzen syndrome. Hum Mol Genet 7: 945957.
  • Carver EA, Oram KF, Gridley T. 2002. Craniosynostosis in Twist heterozygous mice: A model for Saethre-Chotzen syndrome. Anat Rec 268: 9092.
  • Chaudhary LR, Avioli LV. 1997. Activation of extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK2) by FGF-2 and PDGF-BB in normal human osteoblastic and bone marrow stromal cells: Differences in mobility and in-gel renaturation of ERK1 in human, rat, and mouse osteoblastic cells. Biochem Biophys Res Commun 238: 134139.
  • Chen L, Li D, Li C, Engel A, Deng CX. 2003. A Ser250Trp substitution in mouse fibroblast growth factor receptor 2 (Fgfr2) results in craniosynostosis. Bone 33: 169178.
  • Chikazu D, Hakeda Y, Ogata N, Nemoto K, Itabashi A, Takato T, Kumegawa M, Nakamura K, Kawaguchi H. 2000. Fibroblast growth factor (FGF)-2 directly stimulates mature osteoclast function through activation of FGF receptor 1 and p42/p44 MAP kinase. J Biol Chem 275: 3144431450.
  • Cohen MM. 2006. The new bone biology: Pathologic, molecular, and clinical correlates. Am J Med Genet Part A 140A: 26462706.
  • Cohen MM, Maclean RE. 2000. Craniosynostosis: Diagnosis, evaluation, and management. New York: Oxford University Press.
  • Cohen SR, Persing JA. 1998. Intracranial pressure in single-suture craniosynostosis. Cleft Palate Craniofac J 35: 194196.
  • Cohen SR, Mittermiller PA, Meltzer HS, Levy ML, Broder KW, Ozgur BM. 2008. Non-syndromic craniosynostosis: Current treatment options. In: Thaller S, Bradley JP, Gari J, editors. Craniofacial surgery. New York: Informa.
  • Compagni A, Logan M, Klein R, Adams R. 2003. Control of skeletal patterning by EphrinB1-EphB interactions. Dev Cell 5: 217230.
  • Cooper GM, Usas A, Olshanski A, Mooney MP, Losee JE, Huard J. 2009. Ex vivo Noggin gene therapy inhibits bone formation in a mouse model of postoperative resynostosis. Plast Reconstr Surg 123 (2 suppl): 94S103S.
  • Crow JF. 2000. The origins, patterns and implications of human spontaneous mutation. Nat Rev Genet 1: 4047.
  • Davy A, Aubin J, Soriano P. 2004. Ephrin-B1 forward and reverse signaling are required during mouse development. Genes Dev 18: 572583.
  • Delezoide AL, Benoist-Lasselin C, Legeai-Mallet L, Le Merrer M, Munnich A, Vekemans M, Bonaventure J. 1998. Spatio-temporal expression of FGFR 1, 2 and 3 genes during human embryo-fetal ossification. Mech Dev 77: 1930.
  • Eggenschwiler JT, Espinoza E, Anderson KV. 2001. Rab23 is an essential negative regulator of the mouse Sonic hedgehog signalling pathway. Nature 412: 194198.
  • El Ghouzzi V, Le Merrer M, Perrin-Schmitt F, Lajeunie E, Benit P, Renier D, Bourgeois P, Bolcato-Bellemin AL, Munnich A, Bonaventure J. 1997. Mutations of the TWIST gene in the Saethre-Chotzen syndrome. Nat Genet 15: 4246.
  • Eswarakumar VP, Horowitz MC, Locklin R, Morriss-Kay GM, Lonai P. 2004. A gain-of-function mutation of Fgfr2c demonstrates the roles of this receptor variant in osteogenesis. Proc Natl Acad Sci USA 101: 1255512560.
  • Eswarakumar VP, Ozcan F, Lew ED, Bae JH, Tome F, Booth CJ, Adams DJ, Lax I, Schlessinger J. 2006. Attenuation of signaling pathways stimulated by pathologically activated FGF-receptor 2 mutants prevents craniosynostosis. Proc Natl Acad Sci USA 103: 1860318608.
  • Ferreira MP, Collares MVM, Ferreira NP, Kraemer JL, Pereira Filho AA, Pereira Filho GA. 2006. Early surgical treatment of nonsyndromic craniosynostosis. Surg Neurol 65: S22S26.
  • Flück CE, Tajima T, Pandey AV, Arlt W, Okuhara K, Verge CF, Jabs EW, Mendonca BB, Fujieda K, Miller WL. 2004. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley–Bixler syndrome. Nat Genet 36: 228230.
  • Frazier BC, Mooney MP, Losken HW, Barbano T, Moursi A, Siegel MI, Richtsmeier JT. 2008. Comparison of craniofacial phenotype in craniosynostotic rabbits treated with anti-Tgf-β2 at suturectomy site. Cleft Palate Craniofac J 45: 571582.
  • Goriely A, McVean GAT, Röjmyr M, Ingemarsson B, Wilkie AOM. 2003. Evidence for selective advantage of pathogenic FGFR2 mutations in the male germ line. Science 301: 643646.
  • Gosain AKMJ, Gliniak C, Halligan NL. 2009. TGF-β1 RNA interference in mouse primary dura cell culture: Downstream effects on TGF receptors, FGF-2, and FGF-R1 mRNA levels. Plast Reconstr Surg 124: 14661473.
  • Greenwald JA, Mehrara BJ, Spector JA, Warren SM, Fagenholz PJ, Smith LP, Bouletreau PJ, Crisera FE, Ueno H, Longaker MT. 2001. In vivo modulation of FGF biological activity alters cranial suture fate. Am J Pathol 158: 441452.
  • Günther T, Struwe M, Aguzzi A, Schughart K. 1994. Open brain, a new mouse mutant with severe neural tube defects, shows altered gene expression patterns in the developing spinal cord. Development 120: 31193130.
  • Hajihosseini M. 2008. Fibroblast growth factor signaling in cranial suture development and pathogenesis. Front Oral Biol 12: 160177.
  • Hajihosseini MK, Wilson S, De Moerlooze L, Dickson C. 2001. A splicing switch and gain-of-function mutation in FgfR2-IIIc hemizygotes causes Apert/Pfeiffer syndrome-like phenotypes. Proc Natl Acad Sci USA 98: 38553860.
  • Hehr U, Muenke M. 1999. Craniosynostosis syndromes: From genes to premature fusion of skull bones. Mol Genet Metab 68: 139151.
  • Holmes G, Rothschild G, Roy UB, Deng CX, Mansukhani A, Basilico C. 2009. Early onset of craniosynostosis in an Apert mouse model reveals critical features of this pathology. Dev Biol 328: 273284.
  • Howard TD, Paznekas WA, Green ED, Chiang LC, Ma N, Ortiz de Luna RI, Garcia Delgado C, Gonzalez-Ramos M, Kline AD, Jabs EW. 1997. Mutations in TWIST, a basic helix-loop-helix transcription factor, in Saethre-Chotzen syndrome. Nat Genet 15: 3641.
  • Hui CC, Joyner AL. 1993. A mouse model of Greig cephalopolysyndactyly syndrome: The extra-toesJ mutation contains an intragenic deletion of the Gli3 gene. Nat Genet 3: 241246.
  • Jabs EW, Müller U, Li X, Ma L, Luo W, Haworth IS, Klisak I, Sparkes R, Warman ML, Mulliken JB, Snead ML, Maxson R. 1993. A mutation in the homeodomain of the human MSX2 gene in a family affected with autosomal dominant craniosynostosis. Cell 75: 443450.
  • Jenkins D, Seelow D, Jehee FS, Perlyn CA, Alonso LG, Bueno DF, Donnai D, Josifiova D, Mathijssen IMJ, Morton JE, Orstavik KH, Sweeney E, Wall SA, Marsh JL, Nurnberg P, Passos-Bueno MR, Wilkie AO. 2007. RAB23 mutations in Carpenter syndrome imply an unexpected role for hedgehog signaling in cranial-suture development and obesity. Am J Hum Genet 80: 11621170.
  • Jones BM, Jani P, Bingham RM, Mackersie AM, Hayward R. 1992. Complications in paediatric craniofacial surgery: An initial four-year experience. Br J Plast Surg 45: 225231.
  • Kapp-Simon K, Speltz M, Cunningham M, Patel P, Tomita T. 2007. Neurodevelopment of children with single suture craniosynostosis: A review. Childs Nerv Syst 23: 269281.
  • Kasarskis A, Manova K, Anderson KV. 1998. A phenotype-based screen for embryonic lethal mutations in the mouse. Proc Natl Acad Sci USA 95: 74857490.
  • Katoh Y, Katoh M. 2009. FGFR2-related pathogenesis and FGFR2-targeted therapeutics. Int J Mol Med 23: 307311.
  • Kim HJ, Kim JH, Bae SC, Choi JY, Ryoo HM. 2003. The protein kinase C pathway plays a central role in the fibroblast growth factor-stimulated expression and transactivation activity of Runx2. J Biol Chem 278: 319326.
  • Lajeunie E, Merrer ML, Bonaïti-Pellie C, Marchac D, Renier D. 1995. Genetic study of nonsyndromic coronal craniosynostosis. Am J Med Genet 55: 500504.
  • Lekovic GP, Bristol RE, Rekate HL. 2004. Cognitive impact of craniosynostosis. Semin Pediatr Neurol 11: 305310.
  • Lemonnier J, Delannoy P, Hott M, Lomri A, Modrowski D, Marie PJ. 2000. The Ser252Trp fibroblast growth factor receptor-2 (FGFR-2) mutation induces PKC-independent downregulation of FGFR-2 associated with premature calvaria osteoblast differentiation. Exp Cell Res 256: 158167.
  • Lemonnier J, Haÿ E, Delannoy P, Fromigué O, Lomri A, Modrowski D, Marie PJ. 2001a. Increased osteoblast apoptosis in Apert craniosynostosis: Role of protein kinase C and interleukin-1. Am J Pathol 158: 18331842.
  • Lemonnier J, Haÿ E, Delannoy P, Lomri A, Modrowski D, Caverzasio J, Marie PJ. 2001b. Role of N-cadherin and protein kinase C in osteoblast gene activation induced by the S252W fibroblast growth factor receptor 2 mutation in Apert craniosynostosis. J Bone Miner Res 16: 832845.
  • Liu YH, Kundu R, Wu L, Luo W, Ignelzi MA Jr, Snead ML, Maxson RE Jr. 1995. Premature suture closure and ectopic cranial bone in mice expressing Msx2 transgenes in the developing skull. Proc Natl Acad Sci USA 92: 61376141.
  • Liu YH, Tang Z, Kundu RK, Wu L, Luo W, Zhu D, Sangiorgi F, Snead ML, Maxson RE. 1999. Msx2 gene dosage influences the number of proliferative osteogenic cells in growth centers of the developing murine skull: A possible mechanism for MSX2-mediated craniosynostosis in humans. Dev Biol 205: 260274.
  • Lomri A, Lemonnier J, Delannoy P, Marie PJ. 2001. Increased expression of protein kinase Cα, interleukin-1α, and RhoA guanosine 5'-triphosphatase in osteoblasts expressing the Ser252Trp fibroblast growth factor 2 receptor Apert mutation: Identification by analysis of complementary DNA microarray. J Bone Miner Res 16: 705712.
  • Mann MB, Hodges CA, Barnes E, Vogel H, Hassold TJ, Luo G. 2005. Defective sister-chromatid cohesion, aneuploidy and cancer predisposition in a mouse model of type II Rothmund-Thomson syndrome. Hum Mol Genet 14: 813825.
  • Marchac D, Renier D, Broumand S. 1994. Timing of treatment for craniosynostosis and facio-craniosynostosis: A 20-year experience. Br J Plast Surg 47: 211222.
  • Marie PJ, Coffin JD, Hurley MM. 2005. FGF and FGFR signaling in chondrodysplasias and craniosynostosis. J Cell Biochem 96: 888896.
  • McCarthy JG, Cutting CB. 1990. The timing of surgical intervention in craniofacial anomalies. Clin Plast Surg 17: 161182.
  • McCarthy JG, Glasberg SB, Cutting CB, Epstein FJ, Grayson BH, Ruff G, Thorne CH, Wisoff J, Zide BM. 1995. Twenty-year experience with early surgery for craniosynostosis: I. Isolated craniofacial synostosis—Results and unsolved problems. Plast Reconstr Surg 96: 284295; discussion 296–298.
  • McDowell LM, Frazier BA, Studelska DR, Giljum K, Chen J, Liu J, Yu K, Ornitz DM, Zhang L. 2006. Inhibition or activation of Apert syndrome FGFR2 (S252W) signaling by specific glycosaminoglycans. J Biol Chem 281: 69246930.
  • McIntosh IA, Bellus G, Jabs EW. 2000. The pleiotropic effects of fibroblast growth factor receptors in mammalian development. Cell Struct Funct 25: 8596.
  • Meara JG, Smith EM, Harshbarger RJ, Farlo JN, Matar MM, Levy ML. 2005. Blood-conservation techniques in craniofacial surgery. Ann Plast Surg 54: 525529.
  • Merrill AE, Bochukova EG, Brugger SM, Ishii M, Pilz DT, Wall SA, Lyons KM, Wilkie AO, Maxson RE Jr. 2006. Cell mixing at a neural crest-mesoderm boundary and deficient ephrin-Eph signaling in the pathogenesis of craniosynostosis. Hum Mol Genet 15: 13191328.
  • Miraoui H, Oudina K, Petite H, Tanimoto Y, Moriyama K, Marie PJ. 2009. Fibroblast growth factor receptor 2 promotes osteogenic differentiation in mesenchymal cells via ERK1/2 and protein kinase C signaling. J Biol Chem 284: 48974904.
  • Miraoui H, Ringe J, Haupl T, Marie PJ. 2010. Increased EFG- and PDGFα receptor signaling by mutant FGF-receptor 2 contributes to osteoblast dysfunction in Apert craniosynostosis. Hum Mol Genet 19: 16781689.
  • Mooney MP, Losken HW, Siegel MI, Lalikos JF, Losken A, Smith TD, Burrows AM. 1994a. Development of a strain of rabbits with congenital simple nonsyndromic coronal suture synostosis Part I: Breeding demographics, inheritance pattern, and craniofacial anomalies. Cleft Palate Craniofac J 31: 17.
  • Mooney MP, Losken HW, Siegel MI, Lalikos JF, Losken A, Burrows AM, Smith TD. 1994b. Development of a strain of rabbits with congenital simple nonsyndromic coronal suture synostosis Part II: Somatic and craniofacial growth patterns. Cleft Palate Craniofac J 31: 816.
  • Mooney MP, Losken HW, Moursi A, Bradley J, Azari K, Acarturk TO, Cooper G, Thompson B, Opperman LA, Siegel MI. 2007a. Anti-TGF-β2 antibody therapy inhibits postoperative resynostosis in craniosynostotic rabbits. Plast Reconstr Surg 119: 12001212.
  • Mooney MP, Losken HW, Moursi AM, Shand JM, Cooper G, Curry C, Ho L, Burrows A, Stelnicki E, Losee JE, Opperman LA, Siegel MI. 2007b. Postoperative anti-Tgf-β2 antibody therapy improves intracranial volume and craniofacial growth in craniosynostotic rabbits. J Craniofac Surg 18: 336346.
  • Neilson KM, Friesel RE. 1995. Constitutive activation of fibroblast growth factor receptor-2 by a point mutation associated with Crouzon syndrome. J Biol Chem 270: 2603726040.
  • Opperman LA, Nolen AA, Ogle RC. 1997. TGF-β1, TGF-β2, and TGF-β3 exhibit distinct patterns of expression during cranial suture formation and obliteration in vivo and in vitro. J Bone Miner Res 12: 301310.
  • Perlyn CA, Morriss-Kay G, Darvann T, Tenenbaum M, Ornitz DM. 2006. A model for the pharmacological treatment of Crouzon syndrome. Neurosurgery 59: 210215.
  • Persing JA, Nichter LS, Jane JA, Edgerton MT. 1986. External cranial vault molding after craniofacial surgery. Ann Plast Surg 17: 274283.
  • Persing J, Babler W, Winn HR, Jane J, Rodeheaver G. 2009. Age as a critical factor in the success of surgical correction of craniosynostosis. J Neurosurg 54: 601606.
  • Pollock PM, Gartside MG, Dejeza LC, Powell MA, Mallon MA, Davies H, Mohammadi M, Futreal PA, Stratton MR, Trent JM, Goodfellow PJ. 2007. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 26: 71587162.
  • Roth DA, Gold LI, Han VK, McCarthy JG, Sung JJ, Wisoff JH, Longaker MT. 1997a. Immunolocalization of transforming growth factor β1, β2, and β3 and insulin-like growth factor I in premature cranial suture fusion. Plast Reconstr Surg 99: 300309; discussion 310–316.
  • Roth DA, Longaker MT, McCarthy JG, Rosen DM, McMullen HF, Levine JP, Sung J, Gold LI. 1997b. Studies in cranial suture biology: Part I. Increased immunoreativity for TGF-β isoforms (β1, β2, and β3) during rat cranial suture fusion. J Bone Miner Res 12: 311321.
  • Schmidt K, Hughes C, Chudek JA, Goodyear SR, Aspden RM, Talbot R, Gundersen TE, Blomhoff R, Henderson C, Wolf CR, Tickle C. 2009. Cholesterol metabolism: The main pathway acting downstream of cytochrome P450 oxidoreductase in skeletal development of the limb. Mol Cell Biol 29: 27162729.
  • Seymour-Dempsey K, Baumgartner JE, Teichgraeber JF, Xia JJ, Waller AL, Gateno J. 2002. Molding helmet therapy in the management of sagittal synostosis. J Craniofac Surg 13: 631635.
  • Shen K, Krakora S, Cunningham M, Singh M, Wang X, Hu F, Post J, Ehrlich G. 2009. Medical treatment of craniosynostosis: Recombinant Noggin inhibits coronal suture closure in the rat craniosynostosis model. Orthod Craniofac Res 12: 254262.
  • Shukla V, Coumoul X, Wang RH, Kim HS, Deng CX. 2007. RNA interference and inhibition of MEK-ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosis. Nat Genet 39: 11451150.
  • Spector JA, Mathy JA, Warren SM, Nacamuli RP, Song HM, Lenton K, Fong KD, Fang DT, Longaker MT. 2005. FGF-2 acts through an ERK1/2 intracellular pathway to affect osteoblast differentiation. Plast Reconstr Surg 115: 838852.
  • Speltz ML, Kapp-Simon KA, Cunningham M, Marsh J, Dawson G. 2004. Single-suture craniosynostosis: A review of neurobehavioral research and theory. J Pediatr Psychol 29: 651668.
  • Tellado MG, Lema A. 2009. Coronal suturectomy through minimal incisions and distraction osteogenesis are enough without other craniotomies for the treatment of plagiocephaly due to coronal synostosis. J Craniofac Surg 20: 19751977.
  • Thomas GP, Wilkie AO, Richards PG, Wall SA. 2005. FGFR3 P250R mutation increases the risk of reoperation in apparent 'nonsyndromic' coronal craniosynostosis. J Craniofac Surg 16: 347352; discussion 353–354.
  • Tolarova MM, Harris JA, Ordway DE, Vargervik K. 1997. Birth prevalence, mutation rate, sex ratio, parents' age, and ethnicity in Apert syndrome. Am J Med Genet 72: 394398.
  • Turner N, Grose R. 2010. Fibroblast growth factor signalling: From development to cancer. Nat Rev Cancer 10: 116129.
  • Twigg SRF, Kan R, Babbs C, Bochukova EG, Robertson SP, Wall SA, Morriss-Kay GM, Wilkie AOM. 2004. Mutations of ephrin-B1 (EFNB1), a marker of tissue boundary formation, cause craniofrontonasal syndrome. Proc Natl Acad Sci USA 101: 86528657.
  • Twigg SR, Healy C, Babbs C, Sharpe JA, Wood WG, Sharpe PT, Morriss-Kay GM, Wilkie AO. 2009. Skeletal analysis of the Fgfr3(P244R) mouse, a genetic model for the Muenke craniosynostosis syndrome. Dev Dyn 238: 331342.
  • Van Maldergem L, Siitonen HA, Jalkh N, Chouery E, De Roy M, Delague V, Muenke M, Jabs EW, Cai J, Wang LL, Plon SE, Fourneau C, Kestila M, Gillerot Y, Megarbane A, Verloes A. 2006. Revisiting the craniosynostosis-radial ray hypoplasia association: Baller–Gerold syndrome caused by mutations in the RECQL4 gene. J Med Genet 43: 148152.
  • Vortkamp A, Franz T, Gessler M, Grzeschik KH. 1992. Deletion of GLI3 supports the homology of the human Greig cephalopolysyndactyly syndrome (GCPS) and the mouse mutant extra toes (Xt). Mamm Genome 3: 461463.
  • Wang Y, Xiao R, Yang F, Karim BO, Iacovelli AJ, Cai J, Lerner CP, Richtsmeier JT, Leszl JM, Hill CA, Yu K, Ornitz DM, Elisseeff J, Huso DL, Jabs EW. 2005. Abnormalities in cartilage and bone development in the Apert syndrome FGFR2(+/S252W) mouse. Development 132: 35373548.
  • Wang Y, Sun M, Uhlhorn VL, Zhou X, Peter I, Martinez-Abadias N, Hill CA, Percival CJ, Richtsmeier JT, Huso DL, Jabs EW. 2010. Activation of p38 MAPK pathway in the skull abnormalities of Apert syndrome Fgfr2(+/P253R) mice. BMC Dev Biol 10: 22.
  • Warren SM, Brunet LJ, Harland RM, Economides AN, Longaker MT. 2003. The BMP antagonist noggin regulates cranial suture fusion. Nature 422: 625629.
  • Whitaker LA, Munro IR, Salyer KE, Jackson IT, Ortiz-Monasterio F, Marchac D. 1979. Combined report of problems and complications in 793 craniofacial operations. Plast Reconstr Surg 64: 198203.
  • Wieland I, Reardon W, Jakubiczka S, Franco B, Kress W, Vincent-Delorme C, Thierry P, Edwards M, König R, Rusu C, Schweiger S, Thompson E, Tinschert S, Stewart F, Wieacker P. 2005. Twenty-six novel EFNB1 mutations in familial and sporadic craniofrontonasal syndrome (CFNS). Hum Mutat 26: 113118.
  • Wilkie AO. 2005. Bad bones, absent smell, selfish testes: The pleiotropic consequences of human FGF receptor mutations. Cytokine Growth Factor Rev 16: 187203.
  • Wilkie AO. 2007. Cancer drugs to treat birth defects. Nat Genet 39: 10571059.
  • Wilkie AO, Bochukova EG, Hansen RMS, Taylor IB, Rannan-Eliya SV, Byren JC, Wall SA, Ramos L, Venâncio M, Hurst JA, O'Rourke AW, Williams LJ, Seller A, Lester T. 2007. Clinical dividends from the molecular genetic diagnosis of craniosynostosis. Am J Med Genet Part A 143A: 19411949.
  • Yin L, Du X, Li C, Xu X, Chen Z, Su N, Zhao L, Qi H, Li F, Xue J, Yang J, Jin M, Deng C, Chen L. 2008. A Pro253Arg mutation in fibroblast growth factor receptor 2 (Fgfr2) causes skeleton malformation mimicking human Apert syndrome by affecting both chondrogenesis and osteogenesis. Bone 42: 631643.
  • Yoon SR, Qin J, Glaser RL, Jabs EW, Wexler NS, Sokol R, Arnheim N, Calabrese P. 2009. The ups and downs of mutation frequencies during aging can account for the Apert syndrome paternal age effect. PLoS Genet 5: e1000558 [Epub July 10, 2009].
  • Yu K, Herr AB, Waksman G, Ornitz DM. 2000. Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome. Proc Natl Acad Sci USA 97: 1453614541.
  • Zhou YX, Xu X, Chen L, Li C, Brodie SG, Deng CX. 2000. A Pro250Arg substitution in mouse Fgfr1 causes increased expression of Cbfa1 and premature fusion of calvarial sutures. Hum Mol Genet 9: 20012008.